Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kun Run Biotech Raises $8 Million from OrbiMed

publication date: Apr 23, 2010
Kun Run Biotechnology, a biopharma focused on peptide and small molecule drugs, has raised $8 million in a private placement with Caduceus Asia Partners, LP, a fund managed by OrbiMed Advisors, and Mr. Xueyun Cui, who is both Chairman and majority stockholder of Kun Run. In a statement, Mr. Cui said that OrbiMed’s participation would give Kun Run a leg up in its plan to sell products globally. More details...

Stock Symbol: (OTCBB: KURU)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here